LY3871801 for Rheumatoid Arthritis
Trial Summary
What is the purpose of this trial?
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Eligibility Criteria
This trial is for adults with active moderate-to-severe rheumatoid arthritis (RA) who have had RA for at least 3 months and haven't responded well to previous treatments. Participants should have a significant number of swollen and tender joints. Those with severe other diseases or heart, kidney, lung problems, or different inflammatory conditions are excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Phase 2a
Participants receive LY3871801 or placebo administered orally
Treatment Phase 2b
Participants receive different doses of LY3871801 or placebo administered orally
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LY3871801 (Monoclonal Antibodies)
- Placebo ()